Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| N.N. Alexandrov National Cancer Centre | OTHER_GOV |
Not provided
Not provided
Not provided
Not provided
Treatment of patients with urinary incontinence after prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen gel
During the implementation of the project, it is planned to develop a method for the treatment of men urinary incontinence caused by prostatectomy using injection of autologous adipose-derived mesenchymal stem cells mixed with collagen. The positive outlook for the effectiveness of MSCs is due to the following:
In study planing to include 5 patients. MSCs will be isolated from adipose tissue, cultured and then transplanted back to the periurethral area by five point injection in rhabdosphincter and submucosal space of urethra using the cystourethroscope. For injection in submucosal space MSCs (20*10^6 cells) will be mixed with collagen solution (3,5% w|w). Follow up patients monitoring will occur at 1,3,6 and 12 months after injection.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| mesenchymal stem cells | Experimental | Patients with Urinary incontinence receiving standard treatment plus adipose-derived mesenchymal stem cells |
|
| control | Active Comparator | Patients with Urinary incontinence receiving standard treatment |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Autologous adipose-derived mesenchymal stem cells | Biological | Autologous adipose-derived mesenchymal stem cells mixed with collagen solution injected in submucosal space |
|
| Measure | Description | Time Frame |
|---|---|---|
| Number of cured patients | Number of patients cured | 3 months |
| Number of patients with treatment-related adverse events | MSC application related adverse events assessed by blood count, liver and function tests | 4 weeks |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Igor D Volotovski, Dr | Head of the Lab of Institute of Biophysics and Cell Engineering | Study Director |
| Sergey A Krasny, Dr | Deputy Director for Research of the National Cancer Centre | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Institute of Biophysics and Cell Engineering of National Academy of Sciences of Belarus | Minsk | 220072 | Belarus |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Standard treatment according to the Clinical protocols | Other | Standard treatment according to the Clinical protocols |
|
| ID | Term |
|---|---|
| D014549 | Urinary Incontinence |
| ID | Term |
|---|---|
| D014555 | Urination Disorders |
| D014570 | Urologic Diseases |
| D052776 | Female Urogenital Diseases |
| D005261 | Female Urogenital Diseases and Pregnancy Complications |
| D000091642 | Urogenital Diseases |
| D052801 | Male Urogenital Diseases |
| D059411 | Lower Urinary Tract Symptoms |
| D020924 | Urological Manifestations |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided